Atai Life Sciences (ATAI) said Tuesday that topline data from a phase 2a trial showed that a single dose of its drug BPL-003, when given to patients who were also taking defined selective serotonin reuptake inhibitors, produced antidepressive effects of up to three months.
The drug was well-tolerated with no serious adverse events, and an average in-clinic treatment time following dosing of less than two hours, the company said.
The 12-patient study showed average MADRS score reductions of 18 to 19 points up to three months post-treatment, supporting prior monotherapy findings, Atai said.
Atai shares were 3.8% lower in recent premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。